AUBURNDALE, Mass., Jan. 4, 2019 /PRNewswire/ -- Candel Therapeutics, a clinical-stage biotechnology company developing novel cancer immunotherapy therapeutics, today announced that Dr. Estuardo Aguilar-Cordova, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 7:30 a.m. Pacific Time. Dr. Aguilar-Cordova will provide a business overview and update on the company's novel and proprietary late stage immuno-oncology pipeline. The event will be held in San Francisco at the Westin St. Francis.
About Candel Therapeutics
Candel Therapeutics is a Massachusetts based biotechnology company developing its proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform and its rQNestin34.5 platform, for the treatment of solid tumors.
GMCI™ is an "off the shelf" low toxicity adenovirus based immunotherapy that causes immunogenic tumor cell death, stimulating a hyper-immunogenic microenvironment and generating a personalized, robust and precise systemic response from the patient's own immune system against his or her cancer. GMCI™ has been evaluated in 11 completed clinical trials and 5 ongoing clinical trials across multiple indications including prostate, brain, pancreas and lung cancers. With over 1,200 patient doses in 650 patients, GMCI™ has meaningful evidence suggesting it is well tolerated and safe. These studies include a registration clinical trial for the treatment of localized prostate cancer patients under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. If proven efficacious, this product candidate will be the first and only therapeutic pharmaceutical available for localized prostate cancer patients.
rQNestin34.5 is an immuno-oncology approach that uses a genetically modified oncolytic herpes simplex virus engineered for enhanced potency. Conditional ICP34.5 expression in the presence of Nestin greatly improves replication and oncolytic activity of HSV. This product candidate is currently being tested in a Phase 1 clinical study in patients with recurrent malignant glioma.
For more information about Candel Therapeutics and our cancer immunotherapy programs please email info@CandelTX.com.
Media contact:
Sky Striar
JPA Health Communications
617-657-1314
207131@email4pr.com
Website: www.CandelTX.com
SOURCE Candel Therapeutics
